VYNE Therapeutics Inc. (VYNE) Stock Score, Valuation & Financial Research
VYNE Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for VYNE
VYNE Therapeutics Inc. currently has a Wall Street Score of 27/100. The stored market price is $28.56. Its financial score is 27/100. Its valuation score is 0/100. The latest WSS change is -1.8 points. These figures are a research snapshot, not a buy or sell recommendation.
What VYNE Therapeutics Inc. does
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Establishe
VYNE financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $28.56
- Market capitalization:
- $19.1M
- Revenue:
- $955K
- Net income:
- $-42.2M
- Free cash flow:
- $-33.1M
- Cash:
- $24K
- Total debt:
- $0
- EPS:
- -636.98
- Financial score:
- 27/100
- Valuation score:
- 0/100
- Revenue score:
- 33/100
What stands out
- Reported year-over-year revenue growth is +0.7%.
- Free cash flow is $-33.1M, showing cash burn in the current stored period.
- The balance sheet shows $24K of cash versus $0 of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -1.8 points: VYNE decreased 1.8 points because Asset declined by 39.9 points, Capital declined by 2 points, Buffett declined by 2 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 27/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-13.
How to research VYNE
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.